3 Strain Blend

Bio-K+

JUMP TO:
01
Summary

One clinical trial evaluated a probiotic blend of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 in 86 participants with various subtypes of IBS (IBS-D, IBS-C, and IBS-M). This randomized, placebo-controlled study suggested potential benefits for regulating bowel habits, particularly in women and those with IBS-C and IBS-D. However, significant methodological issues undermined the credibility of these findings.

Key concerns included the absence of inferential statistics, reliance on inappropriate calculations and percentages, and subgroup analyses with insufficient sample sizes. Additionally, the study failed to report baseline and post-test characteristics, further diminishing its validity. Our independent statistical analysis based on the available data revealed no statistically significant differences between the probiotic and placebo groups. Consequently, the study has been excluded from our database due to poor evidence quality.

Key Takeaway:

Due to poor evidence quality, the study on this 3-strain probiotic blend for IBS has been excluded from our database. 

Dose:

None recommended due to insufficient evidence.

Our Detailed Calculations:

Note:

  • The probiotic group is labeled as 1 and the placebo group as 2.
  • ns: Not significant
  • SD: Standard Deviation
  • Cohen’s d values indicate small to medium effect sizes, but none reach statistical significance.
  • If gender is not specified, calculations are for measurements taken of both sexes for the evaluated parameters.

 

Reference:

Preston K, Krumian R, Hattner J, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes 2018 Sep 18;9(5):697-706. [doi: 10.3920/BM2017.0105] S 

Read More…

One clinical trial evaluated a probiotic blend of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 in 86 participants with various subtypes of IBS (IBS-D, IBS-C, and IBS-M). This randomized, placebo-controlled study suggested potential benefits for regulating bowel habits, particularly in women and those with IBS-C and IBS-D. However, significant methodological issues undermined the credibility of these findings.

Key concerns included the absence of inferential statistics, reliance on inappropriate calculations and percentages, and subgroup analyses with insufficient sample sizes. Additionally, the study failed to report baseline and post-test characteristics, further diminishing its validity. Our independent statistical analysis based on the available data revealed no statistically significant differences between the probiotic and placebo groups. Consequently, the study has been excluded from our database due to poor evidence quality.

Key Takeaway:

Due to poor evidence quality, the study on this 3-strain probiotic blend for IBS has been excluded from our database. 

Dose:

None recommended due to insufficient evidence.

Our Detailed Calculations:

Note:

  • The probiotic group is labeled as 1 and the placebo group as 2.
  • ns: Not significant
  • SD: Standard Deviation
  • Cohen’s d values indicate small to medium effect sizes, but none reach statistical significance.
  • If gender is not specified, calculations are for measurements taken of both sexes for the evaluated parameters.

 

Reference:

Preston K, Krumian R, Hattner J, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes 2018 Sep 18;9(5):697-706. [doi: 10.3920/BM2017.0105] S 

Read More…
Find a probiotic with Bio-K+

There is insufficient evidence demonstrating benefits for IBS with this probiotic. Therefore, we do not provide guidance on finding a commercial product containing this blend.

One clinical trial evaluated a probiotic blend of Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 in 86 participants with various subtypes of IBS (IBS-D, IBS-C, and IBS-M). This randomized, placebo-controlled study suggested potential benefits for regulating bowel habits, particularly in women and those with IBS-C and IBS-D. However, significant methodological issues undermined the credibility of these findings.

Key concerns included the absence of inferential statistics, reliance on inappropriate calculations and percentages, and subgroup analyses with insufficient sample sizes. Additionally, the study failed to report baseline and post-test characteristics, further diminishing its validity. Our independent statistical analysis based on the available data revealed no statistically significant differences between the probiotic and placebo groups. Consequently, the study has been excluded from our database due to poor evidence quality.

Key Takeaway:

Due to poor evidence quality, the study on this 3-strain probiotic blend for IBS has been excluded from our database. 

Dose:

None recommended due to insufficient evidence.

Our Detailed Calculations:

Note:

  • The probiotic group is labeled as 1 and the placebo group as 2.
  • ns: Not significant
  • SD: Standard Deviation
  • Cohen’s d values indicate small to medium effect sizes, but none reach statistical significance.
  • If gender is not specified, calculations are for measurements taken of both sexes for the evaluated parameters.

 

Reference:

Preston K, Krumian R, Hattner J, et al. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study. Benef Microbes 2018 Sep 18;9(5):697-706. [doi: 10.3920/BM2017.0105] S 

02
Results
Overall evidence quality grade
0%

This probiotic has low to moderate quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2 improve quality-of-life and IBS symptoms: a double-blind, randomised, placebo-controlled study

    • 2018
    • Preston K, Krumian R, Hattner J, et al.

    • Benef Microbes 2018 Sep 18;9(5):697-706

    • DOI: 10.3920/BM2017.0105
    • 100 billion CFU
    • 12 weeks
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED

    • ADULTS

    • ITT,PP (total) n=113,86
      ITT,PP (probiotic) n=76,59
      ITT,PP (placebo) n=37,27
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • Improved distention severity by 50% in women and 89% in men and women combined compared to placebo Improved satisfaction with bowel habits by 43% to 76% depending on gender compared to placebo.

      • IBS-D women had the most pronounced benefit. Improved interference with life by 39% to 144% compared to placebo, with the most pronounced effect in women Improved IBS-QOL overall by 30% but even more significantly in IBS-D by 65% compared to placebo IBS-D QOL in females improved by 75% and for males, 38% compared to placebo.

      • Improved IBS-D stool consistency by 78% to 98% compared to placebo with the most pronounced effects in women Improved IBS-D stool frequency from 35% to 214% with the greatest effect in men

    • Constipation

      • Improved days with pain by 42% compared to placebo in IBS-C women. Improved satisfaction with bowel habits by 30-33% depending on gender compared to placebo.

      • Improved IBS-C QOL by 101% compared to placebo. Improved IBS-C stool consistency by 71% compared to placebo in males. Improved IBS-C stool frequency compared to placebo from 97% to 352% with the greatest effect in men.

    • Bowel Habits

      • Improved days with pain by 42% compared to placebo in IBS-C women. Improved satisfaction with bowel habits by 30-33% depending on gender compared to placebo. Improved IBS-C QOL by 101% compared to placebo.

      • Improved IBS-C stool consistency by 71% compared to placebo in males. Improved IBS-C stool frequency compared to placebo from 97% to 352% with the greatest effect in men.

      • Improved distention severity by 50% in women and 89% in men and women combined compared to placebo Improved satisfaction with bowel habits by 43% to 76% depending on gender compared to placebo. IBS-D women had the most pronounced benefit.

      • Improved interference with life by 39% to 144% compared to placebo, with the most pronounced effect in women. Improved IBS-QOL overall by 30% but even more significantly in IBS-D by 65% compared to placebo IBS-D QOL in females improved by 75% and for males, 38% compared to placebo.

      • Improved IBS-D stool consistency by 78% to 98% compared to placebo with the most pronounced effects in women Improved IBS-D stool frequency from 35% to 214% with the greatest effect in men

      • The probiotic also improved satisfaction with bowel habits by 46% compared to placebo for females of varying subtypes.

    • Global IBS Symptoms

      • There was no significant reduction of 30% compared to placebo in the overall IBS-SSS score or for adequate relief of symptoms after probiotic administration.

    • Abdominal Pain / Discomfort

      • There was no significant reduction of 30% compared to placebo for abdominal pain after probiotic administration.

    • Bloating / Distention

      • Improved distention severity by 50% in women and 89% in men and women combined compared to placebo Improved satisfaction with bowel habits by 43% to 76% depending on gender compared to placebo.

      • IBS-D women had the most pronounced benefit. Improved interference with life by 39% to 144% compared to placebo, with the most pronounced effect in women. Improved IBS-QOL overall by 30% but even more significantly in IBS-D by 65% compared to placebo IBS-D QOL in females improved by 75% and for males, 38% compared to placebo.

      • Improved IBS-D stool consistency by 78% to 98% compared to placebo with the most pronounced effects in women Improved IBS-D stool frequency from 35% to 214% with the greatest effect in men.

    • Gas / Flatulence

      • No data

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • Improved distention severity by 50% in women and 89% in men and women combined compared to placebo Improved satisfaction with bowel habits by 43% to 76% depending on gender compared to placebo. IBS-D women had the most pronounced benefit.

      • Improved interference with life by 39% to 144% compared to placebo, with the most pronounced effect in women. Improved IBS-QOL overall by 30% but even more significantly in IBS-D by 65% compared to placebo IBS-D QOL in females improved by 75% and for males, 38% compared to placebo.

      • Improved IBS-D stool consistency by 78% to 98% compared to placebo with the most pronounced effects in women Improved IBS-D stool frequency from 35% to 214% with the greatest effect in men.

      • Improved days with pain by 42% compared to placebo in IBS-C women. Improved satisfaction with bowel habits by 30-33% depending on gender compared to placebo. Improved IBS-C QOL by 101% compared to placebo.

      • Improved IBS-C stool consistency by 71% compared to placebo in males. Improved IBS-C stool frequency compared to placebo from 97% to 352% with the greatest effect in men.

      • The probiotic also improved IBS QOL in female participants by 84% compared to placebo. Likewise, it improved interference with life by 57% compared to placebo in females of varying subtypes.

    • Miscellaneous Symptoms

      • No data

    • Notes

      • No data